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remaining six program designs can all be considered cost effective depending on 
what the health-care decision makers are ready to pay for gaining a quality-adjusted 
life-year. ConClusions: Based on the results of the simulated screening programs, 
initiation of screening at the age of 75 with repeated screening at 80 years was found 
to be the most cost-effective design of a screening program for unknown AF when 
a QALY is considered to be worth approximately € 50,000.
PMD58
HigHer AccurAcy Of BlOOD glucOse MOnitOring systeMs in tyPe 2 
insulin treAteD DiABetic PAtients in sPAin: clinicAl AnD ecOnOMic 
iMPAct
Khan-Miron A
Universitat Pompeu Fabra, Barcelona, Spain
objeCtives: Accuracy standards of blood glucose monitoring systems have been 
recently revised. The revised standard, ISO 15197:2013, tightens the range of results 
considered accurate from a 20% deviation from the reference value to a 15%. The 
objective of this analysis is to evaluate the economic value of accuracy differences 
between ISO compliant and non ISO compliant meters in Spain, using a model-
ling approach. Methods: Clinical and economic outcomes were simulated over a 
20-years time horizon by means of a Markov model. 4 health states were considered, 
including no event, non-fatal hypoglycemia, fatal hypoglycemia and death due to 
other causes. Model inputs were derived from published sources. Inputs included 
Spanish Type 2 diabetes mellitus (T2DM) insulin-treated population size, risk of 
severe hypoglycemic event (SHE) due to meter error, cost per SHE and rates of death 
due to SHE and other causes. Results: A reduction of the inaccuracy range from 
20% to 15% would translate into a 25.5% reduction of SHE. The incremental cost per 
SHE avoided would be -2,795€ . The reduction in SHE would lead to cost savings of 
135€ per T2DM insulin-treated patient and year. Considering there are 379,728 T2DM 
insulin-treated patients in Spain, the total cost savings would exceed 51€ million, 
meaning 0.9% of total Spanish diabetes expenditure and 0.07% of total Spanish 
health care expenditure. ConClusions: Self-monitoring blood glucose is a key 
component of diabetes management as it is often used in clinical decision making. 
It is therefore critical that these devices are accurate and precise. The results of 
this study might encourage the conversion of all patients using non ISO compli-
ant meters to ISO compliant meters in the European Union, where ISO 15197:2013 
will become mandatory in May 2016. It might also enhance stricter standards in 
countries where these requirements will not be mandatory.
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objeCtives: Bladder cancer (BC) can be life-long and requires intensive and routine 
monitoring and treatment, which makes it costly and impacts on patients’ health 
perception. Hexaminolevulinate is a photosensitizing agent selectively absorbed by 
cancer cells which light up in red when illuminated with blue light, approved for 
improved detection and management of BC. The objective was to evaluate the cost-
consequences of using Hexaminolevulinate-guided blue-light flexible-cystoscopy 
(HBLFC) as an adjunctive to white-light flexible-cystoscopy (WLFC), compared with 
WLFC alone, in the detection of non-muscle invasive BC (NMIBC) one year after 
diagnosis and recurrence. Methods: A cost-consequence model using a combi-
nation of a decision tree and Markov cohort state transition model structure was 
developed using a Swedish setting, Swedish guidelines and a hospital perspective. 
231 patients were followed in an outpatient setting after diagnosed with NMIBC 
and successfully treated with an initial transurethral resection of bladder tumour 
(TURBT).The 231 patients were distributed across all risk groups. The model cap-
tured costs (2014 SEK) of surveillance and treatment of recurrence and progression 
over a 5-year period using 3-month-cycles. Results: The total cost over five years 
was marginally higher, 1.6%, for HBLFC (SEK 14,033,864) compared to WLFC (SEK 
13,815,155) although cost-saving from year 2. HBLFC resulted in reduced resource 
demand versus the comparator (TURBTs: 121.4 vs 126.1; cystectomies: 56.3 vs 58.8; 
operating room [OR] time [hours]: 428.9 vs 447.4; bed days: 18.7 vs 19.5). High-risk 
patients represented the largest share of the costs but also the main benefits in 
clinical outcomes. ConClusions: HBLFC was cost neutral over 5 years and reduced 
the number of bed days and OR time compared to WLFC alone, resulting mainly 
from fewer TURBTs and cystectomies. The greatest overall benefits were seen among 
high-risk patients, but other risk-groups are likely to benefit as well. Future model 
development will include quality-of-life data.
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objeCtives: The use of antibiotic-laden bone cements in surgical operations of 
the hip aims to help prevent surgical site infections (SSIs) and avoid their negative 
consequences. The objective of this study was to evaluate the costs and conse-
quences for the NHS in England and Wales associated with the use of a dual antibi-
otic cement (COPAL® G+C) compared to a single antibiotic cement (PALACOS® R+G) 
in the treatment of fractured neck of femur with hemiarthroplasty. Methods: A de 
novo decision tree model was developed, incorporating relevant clinical events of 
30-day mortality, superficial and deep SSIs, and revision procedures, over a 1 year 
time horizon. Probabilities were informed by published literature and results of a key 
randomised controlled trial comparing the two interventions. Costs were sourced 
by applying the meta-analytic results to U.S. lengths of stay, costs, and practice pat-
terns. We estimated the annual ARI visit rate for the one million member cohort, 
by setting (inpatient, ICU, outpatient) and ARI diagnosis. Results: In the inpatient 
setting, the costs of procalcitonin -guided care for the one million member cohort 
was $2,083,545, compared to $2,780,322, resulting in net savings of nearly $700,000 
to the IDN for the year 2014. The ICU and outpatient setting, the savings to the IDN 
were $73,326 and $5,329,824, respectively, summing up to overall net savings of 
$6,099,927 for the cohort. Results were robust for all ARI diagnoses. For the whole 
U.S. insured population, procalcitonin-guided care would result in $1.6 billion in 
savings annually. ConClusions: Our results show substantial savings associated 
with procalcitonin protocols of ARI across common U.S. treatment settings. These 
results are robust to changes in key parameters, and the savings can be achieved 
without any negative impact on treatment outcomes.
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objeCtives: The purpose of our analysis was to determine the costs of the con-
ventional three-dimensional radiation therapy (3DCRT) and the normal and hypo-
fractionated intensity-modulated radiation therapy (IMRT and HF-IMRT) for the 
treatment of localized prostate cancer, and to compare the treatment costs with 
the reimbursement fees. Methods: The cost-analysis was performed with micro-
costing method based on the data of a Hungarian oncology center from the per-
spective of the health care provider. We estimated the resource use in each phase 
of the radiation therapy process through face-to-face interviews with radiation 
oncologists, radiation therapists and physicists. The average positioning and treat-
ment delivery time were assessed from the data of 100 fractions delivered in 20 
patients. A unit cost for each cost component was calculated based on the actual 
costs retrieved from the accounting system of the oncology center. We assumed the 
irradiation scheme to use a total of 38 fractions in the 3DCRT and IMRT, and 25 frac-
tions in the hypofractionated scheme. Capital costs were taken into consideration in 
the cost calculation. Costs were converted to EUR by applying actual exchange rates 
(1 EUR = 309 HUF). Results: Based on our calculations the expected mean cost of 
patients undergoing 3DCRT, IMRT and HF-IMRT were 2,105 EUR, 3,066 EUR and 2,244 
EUR respectively. The current reimbursement fee for 38 and 25 fractions are 3,513 
EUR and 2,635 EUR respectively. ConClusions: Although IMRT and HF-IMRT has 
already been proven to be cost-effective compared to 3DCRT, the current reimburse-
ment fees do not encourage healthcare providers to use the more effective therapy 
techniques. The revision of intervention codes, DRGs and cost-weights in terms of 
radiation therapies for prostate cancer is desirable in order to resolve this anomaly.
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objeCtives: According to a number of publications frequency of complaints on 
temporomandibular joints (TMJ) ranges from 27 to 76% and is on a third place in 
modern dentistry after other dental diseases such as caries and its complications 
and periodontal pathology. The necessity of high-quality, relevant and available 
for patient diagnosis is increasing. To evaluate and compare the costs for diagnosis 
of patients with possible TMD from the payer’s perspective in the reform period of 
health care system and implementation of health insurance in Ukraine. Methods: 
For the diagnosis of TMJ violations such alternative methods may be used: ortho-
pantomography (OPG), zonography (ZG), ultrasonography (USG), 3D computed 
tomography (3D CT) and magnetic resonance imaging (MRI). From December 2013 
to June 2015 122 patients with suspected TMD at Prosthetic Dentistry Department 
Danylo Halytsky Lviv National Medical University were examined. Results: The 
above mentioned methods singly and in combination were used for diagnosis. The 
costs of examination according to the average data in private and public clinics in 
Lviv are: OPG - 5-7 € ; ZG - 5-7€ , USG - 7-9 € , 3D CT - 18-30 € , MRI - 30-50 € . Resulting 
62 OPG, 22 ZG, 54 USG, 20 3D CT and 2 MRI were conducted. Consequently, OPG, ZG 
and USG are available for most patients, less available is 3D CT. MRI is the most 
limited method. ConClusions: Such diagnostic methods as OPG, ZG and USG are 
the most available for patients. They are informative, have no excessive radiation 
exposure and allow them to re-apply if the forward observation is necessary. In 
some cases the 3D CT method should be combined with USG, so that complex has 
a higher cost. MRI is the “gold” standard for diagnosis, but the high cost and features 
of study may limit its usage.
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objeCtives: The primary objective of this study was to use computer simulations 
to determine the optimal age for initiation of screening for atrial fibrillation and 
to evaluate if repeated screening is of additional value. Methods: This analysis 
was based on a decision-analytic simulation model. More than one billion different 
designs of screening programs for unknown atrial fibrillation were simulated and 
analyzed. Widely accepted decision rules for mutually exclusive programs were used 
to identify optimal designs for screening for unknown atrial fibrillation. Results: 
Costs and effects generated by the 1,073,741,824 possible screening designs was 
calculated and compared. Of all possible programs, 1,073,741,818 designs were ruled 
out from the analysis based on dominance, extended dominance or the fact that 
the program design had an incremental cost of over € 100 000 per gained QALY. The 
